meta
|
evidence
oncology
Living systematic review and meta-analysis
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
1
colorectal cancer (CRC)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
versus all
vs immune chekpoint inhibitors
vs others immune checkpoint inhibitors
vs brentuximab vedotin
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab based treatment
pembrolizumab alone
R/R cHL - second line or more (L2)
1
Comparator:
vs brentuximab vedotin;
Risk of bias:
low;
some concerns;
high;
NA;